BRPI0816852A2 - método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. - Google Patents

método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.

Info

Publication number
BRPI0816852A2
BRPI0816852A2 BRPI0816852A BRPI0816852A BRPI0816852A2 BR PI0816852 A2 BRPI0816852 A2 BR PI0816852A2 BR PI0816852 A BRPI0816852 A BR PI0816852A BR PI0816852 A BRPI0816852 A BR PI0816852A BR PI0816852 A2 BRPI0816852 A2 BR PI0816852A2
Authority
BR
Brazil
Prior art keywords
disorder
subject
disease
biomarker
diagnosing
Prior art date
Application number
BRPI0816852A
Other languages
English (en)
Portuguese (pt)
Inventor
B Marsh Clay
G Piper Melissa
Ismail Noura
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Publication of BRPI0816852A2 publication Critical patent/BRPI0816852A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0816852A 2007-09-14 2008-09-12 método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. BRPI0816852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99380907P 2007-09-14 2007-09-14
US5517808P 2008-05-22 2008-05-22
PCT/US2008/076109 WO2009036236A1 (en) 2007-09-14 2008-09-12 Mirna expression in human peripheral blood microvesicles and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0816852A2 true BRPI0816852A2 (pt) 2017-06-06

Family

ID=40452488

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816852A BRPI0816852A2 (pt) 2007-09-14 2008-09-12 método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.

Country Status (10)

Country Link
US (3) US8455199B2 (cg-RX-API-DMAC7.html)
EP (3) EP2610342B1 (cg-RX-API-DMAC7.html)
JP (1) JP5624470B2 (cg-RX-API-DMAC7.html)
CN (2) CN101842484B (cg-RX-API-DMAC7.html)
AU (1) AU2008298744B8 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816852A2 (cg-RX-API-DMAC7.html)
CA (1) CA2699646A1 (cg-RX-API-DMAC7.html)
ES (2) ES2419129T3 (cg-RX-API-DMAC7.html)
IL (2) IL204484A (cg-RX-API-DMAC7.html)
WO (1) WO2009036236A1 (cg-RX-API-DMAC7.html)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Institute, Inc. método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2117305A4 (en) 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOSOMAL COMPONENTS FOR USE AS A VACCINATE
CA2690749A1 (en) * 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
EP2613149B1 (en) 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
EP2650383A1 (en) 2007-08-03 2013-10-16 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
ES2419129T3 (es) 2007-09-14 2013-08-19 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo
CN101424640B (zh) * 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
KR20100127768A (ko) * 2008-02-01 2010-12-06 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
US20110143959A1 (en) * 2008-08-13 2011-06-16 Rosetta Genomics Ltd. Compositions and methods for determining the prognosis of bladder urothelial cancer
WO2010062706A2 (en) 2008-10-30 2010-06-03 Caris Mpi, Inc. Methods for assessing rna patterns
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
RU2400209C1 (ru) * 2009-04-17 2010-09-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и сахарном диабете ii типа
RU2400203C1 (ru) * 2009-04-17 2010-09-27 Илья Николаевич Медведев Способ уменьшения содержания микровезикул в крови при артериальной гипертонии, дислипидемии и абдоминальном ожирении
WO2010126370A2 (en) * 2009-04-29 2010-11-04 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
EP2336353A1 (en) * 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
DK2454588T3 (en) * 2009-07-16 2015-09-28 Gen Hospital Corp Nucleic acid
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
JP6143041B2 (ja) * 2009-09-30 2017-06-07 公益財団法人ヒューマンサイエンス振興財団 大腸がん検査キット
WO2011039757A2 (en) * 2009-10-04 2011-04-07 Rosetta Genomics Ltd. Compositions and methods for prognosis of renal cancer
EP2496714B1 (en) 2009-11-04 2016-08-31 DiamiR, LLC Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found MATERIALS AND METHODS FOR INFLUENCING GROWTH, MIGRATION AND INVASION OF TUMOR CELLS
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
CN102080083B (zh) * 2009-12-01 2013-02-27 中国科学院上海药物研究所 人miR-149反义核酸及其应用
CN102080086B (zh) * 2009-12-01 2012-12-26 中国科学院上海药物研究所 人miR-133a反义核酸及其应用
US20120302626A1 (en) * 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
CN102892897B (zh) * 2009-12-24 2016-08-03 复旦大学 用于肺癌的微rna表达谱分析的组合物和方法
WO2011076147A1 (en) * 2009-12-24 2011-06-30 Fudan University Plasma-based micro-rna biomarkers and methods for early detection of colorectal cancer
WO2011076141A1 (en) * 2009-12-24 2011-06-30 Fudan University Diagnostic kits comprising microrna biomarkers and methods for diagnosis of hepatocellular cancer
CN102770560B (zh) * 2009-12-24 2015-11-25 复旦大学 用于早期检测结直肠癌的基于血浆的微rna生物标记及方法
CN102892898B (zh) * 2009-12-24 2016-03-09 复旦大学 用于肝细胞癌诊断的含微rna生物标记的诊断试剂盒和方法
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
JP2011211955A (ja) * 2010-03-31 2011-10-27 Toray Ind Inc 肝ガン患者予後予測用組成物及び方法
US9469876B2 (en) * 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EP2559442B1 (en) * 2010-04-13 2017-12-06 Jiangsu Mingma Biotech Co., Ltd Method for regulating microrna content in organisms and uses thereof
EP2566973A4 (en) * 2010-05-04 2013-11-27 Medimmune Llc OPTIMIZED DIAGNOSIS AND TREATMENT OF MUSCLE DISTORTIONS
AU2011261213B2 (en) 2010-06-04 2015-05-21 Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
CN102985563A (zh) * 2010-06-23 2013-03-20 香港中文大学 结肠直肠癌的微rna标志物
US20130139273A1 (en) * 2010-06-24 2013-05-30 The Ohio State University Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN103221542A (zh) * 2010-09-27 2013-07-24 萨班哲大学 miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
WO2012064993A1 (en) 2010-11-10 2012-05-18 Exosome Diagnosties, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
US8889649B2 (en) * 2010-11-12 2014-11-18 National University Corporation Ehime University Composition containing antisense oligonucleotide to micro RNA
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2012083005A2 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
CN102140465B (zh) * 2010-12-30 2013-06-12 苏州吉玛基因股份有限公司 人miR-1249反义核酸及其应用
CN102146412B (zh) * 2011-01-11 2012-10-03 中山大学 一种小分子非编码RNA 基因hsa-miR-29b 及其应用
WO2012097261A2 (en) 2011-01-14 2012-07-19 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
JP6021893B2 (ja) 2011-04-18 2016-11-09 ディアミール, エルエルシーDiamir, Llc 軽度認知機能障害（ＭＣＩ）およびアルツハイマー病（ＡＤ）の早期検出ならびにモニタリングのために体液からのｍｉＲＮＡを使用する方法
EP2596136B1 (en) * 2011-05-06 2014-07-16 Zhongshan Hospital Fudan University Marker consisting of plasma microrna and new method for diagnosis of hepatocellular carcinoma
JP6154809B2 (ja) 2011-06-27 2017-06-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を示すマイクロｒｎａバイオマーカー
CN102250904B (zh) * 2011-07-13 2013-11-13 中国科学技术大学 一种预防和/或治疗黑色素瘤的药物
WO2013022786A2 (en) * 2011-08-05 2013-02-14 University Of Louisville Research Foundation, Inc. Microrna biomarkers
CN102433339B (zh) * 2011-09-16 2012-10-03 山东莱博生物科技有限公司 一种HCV核酸适配体及其在制备HCV-cAg检测试剂盒中的应用
CN103857796A (zh) * 2011-09-16 2014-06-11 Lsip基金运营联合公司 膀胱癌细胞的检测方法、用于膀胱癌细胞的检测方法的引物及膀胱癌标记物
AU2013201303C1 (en) 2011-10-06 2016-06-23 MiRagen Therapeutics, Inc. Control of whole body energy homeostasis by microRNA regulation
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
EP2584040A1 (en) * 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
JP2015501843A (ja) * 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
ES2432853B1 (es) 2011-12-15 2015-03-09 Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal Metodo para el diagnostico y/o pronostico de dano renal agudo
CN102533979A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-520水平原位杂交检测试剂盒及检测方法和应用
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
CN103372218B (zh) * 2012-04-19 2016-05-04 中国科学院上海生命科学研究院 自身免疫性疾病相关的microRNA及其应用
WO2013165320A1 (en) * 2012-05-04 2013-11-07 Agency For Science, Technology And Research Treating cancer by increasing expression of socs6
CN102676524B (zh) * 2012-05-16 2013-04-03 北京旷博生物技术有限公司 乳腺癌分子标志物miR-147a
CN102676522B (zh) * 2012-05-16 2013-04-10 北京旷博生物技术有限公司 乳腺癌分子标志物miR-195-5p
CN107236735B (zh) 2012-06-21 2019-11-08 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CN102839172B (zh) * 2012-08-24 2013-09-25 中国医科大学附属第一医院 HIV感染疾病进展分子标志物miR-503
CN102839173B (zh) * 2012-08-24 2013-09-04 中国医科大学附属第一医院 HIV感染疾病进展分子标志物miR-200c
KR20150090072A (ko) 2012-10-23 2015-08-05 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 압타머 및 이의 용도
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP2733219B1 (en) * 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Diagnostic miRNA markers for Alzheimer
EP2733220B1 (en) 2012-11-16 2017-10-18 Siemens Aktiengesellschaft Novel miRNA as a diagnostic marker for Alzheimer's Disease
US10011873B2 (en) 2012-11-16 2018-07-03 Universitat Des Saarlandes Diagnostic miRNA markers for Parkinson disease
EP2746406B1 (en) * 2012-12-18 2017-08-23 Samsung Electronics Co., Ltd. Composition and kit for diagnosing breast cancer including miRNAs within vesicle, and method of diagnosing breast cancer using the same
JP6441567B2 (ja) * 2012-12-18 2018-12-19 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． 小胞内のポリヌクレオチドを含む乳がん診断用組成物及びキット、並びにそれを利用した乳がん診断方法
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
US9193970B1 (en) * 2013-03-14 2015-11-24 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
US9970012B2 (en) 2013-03-14 2018-05-15 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
US9546366B2 (en) 2013-03-14 2017-01-17 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
EP2971162B1 (en) 2013-03-15 2019-05-08 Board Of Regents, The University Of Texas System Mirna biogenesis in exosomes for diagnosis and therapy
WO2015020122A1 (ja) * 2013-08-08 2015-02-12 国立大学法人 大阪大学 尿路上皮癌の診断または治療剤
ES2813699T3 (es) 2013-11-18 2021-03-24 Diamir Llc Métodos de uso de miARN de fluidos corporales para la detección y monitoreo de la enfermedad de Parkinson (PD)
CN103602747B (zh) * 2013-11-28 2014-11-05 山东大学齐鲁医院 一种用于膀胱癌血清miRNA检测的内参及其检测引物与应用
EP3083987B1 (en) * 2013-12-19 2020-08-05 Hummingbird Diagnostics GmbH Determination of platelet-mirnas in alzheimer's disease
US9758773B2 (en) 2014-02-14 2017-09-12 Agilent Technologies, Inc. Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood
JP6415829B2 (ja) * 2014-02-28 2018-10-31 キヤノンメディカルシステムズ株式会社 検体に含まれるエキソソームの特性を判定する方法、診断方法および装置
CN104928360B (zh) * 2014-08-15 2018-04-24 深圳市晋百慧生物有限公司 用于检测肠癌的标记物及其应用
BR112017015618A2 (pt) 2015-01-20 2018-04-10 Miragen Therapeutics Inc inibidores de mir-92 e usos destes.
CA2976577C (en) 2015-02-11 2024-11-19 Aarhus Universitet MICRORNA-BASED METHOD FOR THE EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
EP3262186B1 (en) 2015-02-27 2019-04-03 QIAGEN GmbH A microrna-based method for assessing the prognosis of a prostate cancer patient
US10738360B2 (en) * 2015-03-13 2020-08-11 Hiroshima University Method for assisting detection of alzheimer'S disease or mild cognitive impairment
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
CN106729750A (zh) * 2015-11-20 2017-05-31 昆山彭济凯丰生物科技有限公司 通过miR-183治疗高血脂、脂肪肝、二型糖尿病和降低体重的方法和药物及它们的应用
ITUB20155765A1 (it) * 2015-11-20 2017-05-20 Braindtech S R L Metodi per diagnosi, prognosi e monitoraggio terapeutico di patologie neurologiche, neurodegenerative e infiammatorie basati su microRNA contenuto in microvescicole microglia
CN105400785A (zh) * 2015-12-01 2016-03-16 中国人民解放军第四军医大学 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用
CN105586401A (zh) * 2015-12-14 2016-05-18 常州杰傲医学检验所有限公司 一种用于乳腺癌诊断的miRNA标志物、其应用及诊断试剂盒
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105567826A (zh) * 2016-01-25 2016-05-11 苏州大学附属第二医院 has-miR-29b-3p的检测
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105755123A (zh) * 2016-03-21 2016-07-13 河北医科大学第医院 一种结直肠癌相关的标志物、其引物及应用
WO2017165458A1 (en) 2016-03-21 2017-09-28 Diamir, Llc Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
CN105603113B (zh) * 2016-03-30 2019-02-05 江苏省疾病预防控制中心 HIV-1早期感染相关的血清miRNA在制备试剂盒中的应用
WO2017205686A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
US11584932B2 (en) * 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN108938659A (zh) * 2017-05-19 2018-12-07 昆山彭济凯丰生物科技有限公司 一种调节食欲和体重的方法和药物及它们的应用
WO2019008415A1 (en) * 2017-07-05 2019-01-10 Datar Rajan EXOSOMED AND PBMC GENE EXPRESSION ANALYSIS FOR CANCER CARE
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
CN107557467B (zh) * 2017-08-10 2021-05-11 李永东 一种与脑动脉瘤相关的临床标志物及其应用
JP2019050772A (ja) * 2017-09-15 2019-04-04 国立大学法人 熊本大学 ワクチン接種後副反応を予測する検査方法
EP3724334A1 (en) * 2017-12-14 2020-10-21 Unicyte EV AG Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer
WO2019144183A1 (en) * 2018-01-23 2019-08-01 La Trobe University Biomarkers of colorectal cancer
CN108295268A (zh) * 2018-02-05 2018-07-20 苏州吉玛基因股份有限公司 与肝癌诊疗相关的血清外泌体hsa-miR-93及其应用
EP4498086A3 (en) 2018-02-13 2025-04-02 Toray Industries, Inc. Kit or device and method for detecting dementia
CN108103202A (zh) * 2018-03-06 2018-06-01 苏州吉玛基因股份有限公司 与肝癌诊疗相关的7种血清外泌体miRNAs及其应用
CN108546752B (zh) * 2018-04-20 2021-08-31 南京医科大学 检测和/或预测人类巨大儿的miRNA标志物或其组合及其应用
CN108676880B (zh) * 2018-05-24 2021-01-01 武汉大学 一种人血清afp阴性肝细胞癌检测试剂盒
CN109022587B (zh) * 2018-09-13 2022-02-22 南京求臻基因科技有限公司 一种急性髓系白血病的miRNA标志物及其应用
KR102256747B1 (ko) * 2018-10-30 2021-05-25 가톨릭대학교 산학협력단 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도
KR102131519B1 (ko) * 2018-10-30 2020-07-07 가톨릭대학교 산학협력단 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도
CN109295213A (zh) * 2018-11-01 2019-02-01 中国人民解放军第00医院 免疫性血小板减少症的miRNA标志物及试剂盒和应用
CN109295001A (zh) * 2018-11-14 2019-02-01 姜大奎 一种脐带间充质干细胞复合外泌体及其制备方法
SG11202106638UA (en) * 2018-12-19 2021-07-29 Agency Science Tech & Res Method of diagnosing gastric cancers using micrornas
CN109971851A (zh) * 2019-01-22 2019-07-05 宁波大学 MiR-125b-2-3p作为鉴别诊断肾癌亚型的分子标志物及其在肿瘤转移中的用途
CN109777874B (zh) * 2019-01-29 2022-11-11 上海长海医院 一种适用于胰腺导管腺癌诊断及预后判断的血浆外泌体miRNA标志物及应用
CN109837343B (zh) * 2019-02-22 2024-03-01 中国科学院北京基因组研究所 早期肺腺癌特异性外泌体miRNA及其应用
US10900091B2 (en) * 2019-03-15 2021-01-26 The Chinese University Of Hong Kong miR-133a as a marker for colorectal cancer
CN110699450A (zh) * 2019-05-22 2020-01-17 璞晞（广州）生物免疫技术有限公司 miRNA生物标志物在肝脏疾病诊断和预后判断中的应用
CN110791560B (zh) * 2019-11-06 2021-09-14 中国医学科学院医药生物技术研究所 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
US12091716B2 (en) 2020-01-15 2024-09-17 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating traumatic brain injury
ES2856232B2 (es) * 2020-03-25 2023-11-24 Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos
WO2021240533A1 (en) * 2020-05-29 2021-12-02 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
US20220017971A1 (en) * 2020-07-15 2022-01-20 Kookmin University Industry Academy Cooperation Foundation Composition for predicting chemotherapy resistance of ovarian cancer and use thereof
CN112494654B (zh) * 2020-12-10 2021-12-17 暨南大学附属第一医院（广州华侨医院） 包含LncRNA HCG18抑制剂的药物组合物及其应用
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
CN115192710A (zh) * 2022-05-27 2022-10-18 华南理工大学 一种miRNA-200s保护剂在制备神经系统疾病类药物中的应用和药物及模型构建方法
CN117802232B (zh) * 2022-09-30 2025-08-19 上海思路迪生物医学科技有限公司 血液小型胞外囊泡miRNA在卵巢癌诊断中的应用
CN115944646B (zh) * 2022-12-30 2025-12-30 南华大学附属第一医院 MicroRNA-32-5p在制备抗骨质疏松症药物中的应用
ES2981248A1 (es) * 2023-03-09 2024-10-07 Servicio Andaluz De Salud Panel de microARNs como biomarcadores de alopecia areata severa
CN117821577B (zh) * 2023-10-19 2024-08-23 长沙干细胞与再生医学工业技术研究院有限公司 一种有效治疗卵巢功能减退的羊膜间充质干细胞的筛选方法
CN119524005B (zh) * 2024-11-14 2025-07-25 广东医科大学附属医院 干预B细胞miR-330-5p在制备治疗SLE药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089181A (en) 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20030036077A1 (en) 2001-05-31 2003-02-20 Chronix Biomedical Methods for generating an mRNA expression profile from an ecellular mRNA containing blood sample and using the same to identify functional state markers
US20050158708A1 (en) 2001-06-06 2005-07-21 Iris Alroy Methods and compositions related to tagging of membrane surface proteins
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US20050064470A1 (en) * 2003-07-17 2005-03-24 Rana Tariq M. High throughput screening methods for identifying RNA binding compounds
WO2005114192A1 (en) 2004-05-13 2005-12-01 Centre National De La Recherche Scientifique A device for binding a target entity to a bait entity and detection methods using the same
EP1771563A2 (en) * 2004-05-28 2007-04-11 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007084962A2 (en) 2006-01-18 2007-07-26 The Regents Of The University Of California A fluid membrane-based ligand display system for live cell assays and disease diagnosis applications
EP2613149B1 (en) * 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
ES2419129T3 (es) 2007-09-14 2013-08-19 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes

Also Published As

Publication number Publication date
EP2190992A4 (en) 2011-02-23
EP2190992A1 (en) 2010-06-02
US8455199B2 (en) 2013-06-04
CN101842484B (zh) 2015-07-29
EP3112464A1 (en) 2017-01-04
IL236831A0 (en) 2015-03-31
CN104975089A (zh) 2015-10-14
US10030273B2 (en) 2018-07-24
CN101842484A (zh) 2010-09-22
AU2008298744B8 (en) 2015-01-15
ES2575868T3 (es) 2016-07-01
JP5624470B2 (ja) 2014-11-12
US20130316925A1 (en) 2013-11-28
EP2610342B1 (en) 2016-05-04
IL204484A (en) 2015-02-26
US20170009306A1 (en) 2017-01-12
EP2190992B1 (en) 2013-04-03
WO2009036236A1 (en) 2009-03-19
US20100279292A1 (en) 2010-11-04
ES2419129T3 (es) 2013-08-19
JP2010538653A (ja) 2010-12-16
AU2008298744A8 (en) 2015-01-15
AU2008298744A1 (en) 2009-03-19
EP2610342A1 (en) 2013-07-03
AU2008298744B2 (en) 2014-09-04
CA2699646A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
BRPI0816852A2 (pt) método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.
Li et al. Particulate matter‐induced epigenetic changes and lung cancer
BR112013006683A2 (pt) diagnóstico de câncer de mama
Nosho et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
Jenkinson et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
Cheng et al. The current understanding of asbestos-induced epigenetic changes associated with lung cancer
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
BR112012017084A2 (pt) métodos para previsão de resposta de câncer de mama triplo-negativo à terapia
BRPI0908065A2 (pt) Métodos para tratar um paciente que possui um ifn do tipo i ou doença ou distúrbio mediado por ifnalfa, para neutralizar um perfil de marcador mirna diferencialmente regulado em um paciente, para monitorar ou prognosticar uma progressão da doença inflamatória e da doença miosite de um paciente, para monitorar a progressão da doença inflamatória ou autoimune e da doença miosite de um paciente e para tratar um paciente com miosite
BRPI0807236A2 (pt) métodos para determinar uma suscetibilidade para câncer de próstata em um indivíduo humano, para identificar um marcador para uso em avaliação de suscetibilidade para câncer de próstata e para genotipificar uma amostra de ácido nucleico obtida de um indivíduo humano sob risco de, ou diagnosticado com, câncer de prostáta, para avaliar um indivíduo humano para probabiliade da resposta a um agente terapêutico para prevenir e/ou melhorar sintomas associados com câncer de próstata, para predizer prognóstico de um indivíduo diagnosticado com câncer e para monitorar progresso de um tratamento de um indivíduo sofrendo tratamento para câncer de próstata, kit para avaliar suscetibilidade para câncer de próstata em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e , aparelho para determinar um indicador genético para câncer de próstata em um indivíduo humano.
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
WO2012109632A3 (en) Crown-like structures as a biomarker for cancer risk and cancer prognosis
Gigante et al. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy
WO2012010871A3 (en) Systems and methods for medical data processing and analysis
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
Morhij et al. The modified Glasgow prognostic score in patients undergoing surgery for bone and soft tissue sarcoma
Maher et al. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK® trial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]